Vir Biotechnology, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · San Francisco, CA
VIR chart
What traders are saying about $VIR
Latest postsVir Biotechnology, Inc. news
- Vir Biotechnology (NASDAQ:VIR) Stock Gets Price Target Bump from Morgan Stanley
MarketBeat ·
- State Street Corporation Reveals 4.6% Ownership Stake in Vir Biotechnology Inc
Kalkine Media ·
- A 7.82 million-share stake in Vir Biotechnology (VIR) is reported by State Street.
Stock Titan ·
- Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48
marketbeat.com ·
- Vir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data - Slideshow
Seeking Alpha ·
- Vir Biotechnology: Fairly Valued After Phase 3 Success?
Seeking Alpha ·
- Vir Biotechnology’s hepatitis D drug scores in Phase II and Phase III trials
clinicaltrialsarena.com ·
- Is Vir Biotechnology (VIR) A Bargain After Its Hepatitis Delta Phase 3 Win?
Yahoo Finance ·
- Vir Biotechnology delivers clinical milestones in hepatitis delta with ECLIPSE 1 and SOLSTICE studies
Traders Union ·
- Vir, A Gilead Rival, Shoots To Two-Year High On Its 'Clean Win' In Hepatitis D Treatment
Yahoo Finance ·
- Gilead Rival Shoots To Two-Year High On Hepatitis D News
Investor's Business Daily ·
- Vir Biotechnology (VIR) Posts Positive Phase 3 HDV Data With Durable Follow Through
Simply Wall St ·
Vir Biotechnology, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $68.6M | $74.2M | $86.2M | $1.62B |
| Net income | -$438.0M | -$522.0M | -$615.1M | $515.8M |
| Diluted EPS | $-3.16 | $-3.83 | $-4.59 | $3.83 |
| Total assets (year end) | $1.00B | $1.40B | $1.92B | $2.80B |
| Cash and equivalents (year end) | $232.2M | $222.9M | $241.6M | $848.6M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Vir Biotechnology, Inc.
- Ticker
- VIR (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- San Francisco, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1706431
Frequently asked questions
What exchange is Vir Biotechnology, Inc. listed on?
Vir Biotechnology, Inc. trades on the Nasdaq under the ticker symbol VIR.
What industry is Vir Biotechnology, Inc. in?
Vir Biotechnology, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Vir Biotechnology, Inc. headquartered?
Vir Biotechnology, Inc.'s business address on file with the SEC is in San Francisco, CA.
When does Vir Biotechnology, Inc.'s fiscal year end?
Vir Biotechnology, Inc.'s fiscal year ends on December 31.
How much revenue did Vir Biotechnology, Inc. report?
Vir Biotechnology, Inc. reported $68.6M in revenue for calendar year 2025, according to its SEC filings.